A carregar...
Is reluctance to share Alzheimer’s disease biomarker status with a study partner a barrier to preclinical trial recruitment?
BACKGROUND: Preclinical Alzheimer’s disease clinical trials test candidate treatments in individuals with biomarker evidence but no cognitive impairment. Participants are required to co-enroll with a knowledgeable study partner, to whom biomarker information is disclosed. OBJECTIVE: We investigated...
Na minha lista:
| Publicado no: | J Prev Alzheimers Dis |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8112206/ https://ncbi.nlm.nih.gov/pubmed/33336225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14283/jpad.2020.36 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|